NetworkNewsWire Editorial Coverage : The emergence of psychedelic therapies as a popular investment a few years ago was mostly underscored by investors that rode the cannabis wave seeing a brand-new ...
Nuvalent, Inc. , a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that James Porter, Ph.D., ...
纽约 - 专注于开发脑健康疾病治疗方法的生物制药公司Mind Medicine (MindMed) Inc. (NASDAQ:MNMD)被选入纳斯达克生物技术指数 (NBI)。该公司将于2024年12月23日开盘时正式纳入指数。目前,该公司市值约5.3亿美元,根据 InvestingPro 分析,其财务健康状况获得FAIR评级。
Bio-Techne Corporation , a leader in automated platforms for biotherapeutic characterization, today announced a co-marketing and co-promotion agreement with Waters Corporation aimed at expanding the ...
MindMed has announced the dosing of the first patient in its phase 3 Voyage study of MM120 ODT, a pharmaceutically optimised form of lysergide D-tartrate (LSD) for treating Generalised Anxiety ...